{{Drugbox
| verifiedrevid = 457797273
| IUPAC_name = methyl (5-benzoyl-1''H''-benzimidazol-2-yl)carbamate
| image = Mebendazol.svg
| width = 300
| image2 = Mebendazole3DanJ.gif
<!--Clinical data-->
| tradename = Vermox<ref>{{cite book|last1=Ebadi|first1=Manuchair|title=Desk reference of clinical pharmacology|date=2008|publisher=CRC Press|location=Boca Raton|isbn=9781420047448|page=403|edition=2|url=https://books.google.ca/books?id=ihxyHbnj3qYC&pg=PA403|access-date=2016-03-15|archive-date=2019-09-01|archive-url=https://web.archive.org/web/20190901115909/https://books.google.ca/books?id=ihxyHbnj3qYC&pg=PA403|dead-url=no}}</ref>
| Drugs.com = {{drugs.com|monograph|mebendazole}}
| MedlinePlus = a682315
| pregnancy_AU = B3
| pregnancy_US = C
| legal_AU = S2
| legal_CA = OTC
| legal_UK = GSL
| legal_US = Rx-only
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability = 2-10%
| protein_bound = 95%
| metabolism = [[肝臟|肝臟]]（大部分）
| elimination_half-life = 3-6小時
| excretion = 糞便、尿液（5-10%）
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 31431-39-7
| ATC_prefix = P02
| ATC_suffix = CA01
| ATC_supplemental = {{ATCvet|P52|AC09}}
| PubChem = 4030
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00643
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3890
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 81G6I5V05I
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00368
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 6704
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 685
<!--Chemical data-->
| C=16 | H=13 | N=3 | O=3
| molecular_weight = 295.293 g/mol
| smiles = O=C(c2cc1c(nc(n1)NC(=O)OC)cc2)c3ccccc3
| InChI = 1/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21)
| InChIKey = OPXLLQIJSORQAM-UHFFFAOYAP
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = OPXLLQIJSORQAM-UHFFFAOYSA-N
| melting_point = 288.5
}}
<!-- Definition and medical uses -->
'''甲苯咪唑'''（英語：Mebendazole，簡稱'''MBZ'''），又名'''安樂士'''、'''美鞭達唑'''，為治療多種[[寄生蟲|寄生蟲]]感染的指定用藥<ref name="AHFS2015" />。治療對象包含[[蛔蟲|蛔蟲]]、[[蟯蟲|蟯蟲]]、[[線蟲|線蟲]]、[[絛蟲|絛蟲]]、{{Le|鉤蟲|hookworm}}、[[滴蟲|滴蟲]]、[[囊蟲病|包囊蟲]]，以及[[鞭蟲|鞭蟲]]類的感染<ref name=AHFS2015/>。該藥屬於口服藥物<ref name=AHFS2015>{{cite web|title=Mebendazole|url=http://www.drugs.com/monograph/mebendazole.html|publisher=The American Society of Health-System Pharmacists|accessdate=Aug 18, 2015|archive-date=2015-09-07|archive-url=https://web.archive.org/web/20150907003126/http://www.drugs.com/monograph/mebendazole.html|dead-url=no}}</ref>。

<!-- Side effects -->
甲苯咪唑的藥物耐受性很高<ref name=AHFS2015/>。常見的副作用有[[頭痛|頭痛]]、嘔吐以及[[耳鳴|耳鳴]]<ref name=AHFS2015/>。使用過大劑量的話恐有[[骨髓抑制|骨髓抑制]]的疑慮<ref name=AHFS2015/> 。在懷孕期間使用的安全性之研究尚不明確<ref name=AHFS2015/> 。甲苯咪唑是種可廣泛使用[[苯並咪唑|苯並咪唑]]類的{{Le|驅蟲藥劑|Anthelmintic}}<ref name=AHFS2015/>。

<!-- History, society and culture -->
甲苯咪唑在1971年開始正式使用<ref>{{cite book|last1=Mehlhorn|first1=Heinz|title=Encyclopedic reference of parasitology. 107 tables|date=2001|publisher=Springer|location=Berlin [u.a.]|isbn=9783540668299|page=259|edition=2|url=https://books.google.ca/books?id=OBZbR4vpg0YC&pg=PA259|access-date=2016-03-15|archive-date=2020-01-13|archive-url=https://web.archive.org/web/20200113164611/https://books.google.ca/books?id=OBZbR4vpg0YC&pg=PA259|dead-url=no}}</ref>，是名列[[世界衛生組織基本藥物標準清單|世界衛生組織基本藥物標準清單]]中的藥品，也是基礎[[醫療系統|醫療系統]]裡很重要的藥物之一<ref>{{cite web|title=WHO Model List of EssentialMedicines|url=http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|work=World Health|accessdate=2015-04-01|archive-date=2014-04-23|archive-url=https://web.archive.org/web/20140423005004/http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|dead-url=no}}</ref>。此藥也是作為[[通用名药物|通用名藥品]]在使用。單劑的量販價大約介於0.004到0.04美元間<ref name=GlobP2014>{{cite web|title=Mebendazole|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=MEB100T&s_year=2014&year=2014&str=100%20mg&desc=Mebendazole&pack=new&frm=TAB-CAP&rte=PO&class_code2=06%2E1%2E1%2E&supplement=&class_name=%2806%2E1%2E1%2E%29Intestinal%20anthelminthics%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=18 August 2015|deadurl=yes|archiveurl=https://web.archive.org/web/20170305003745/http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=MEB100T&s_year=2014&year=2014&str=100%20mg&desc=Mebendazole&pack=new&frm=TAB-CAP&rte=PO&class_code2=06%2E1%2E1%2E&supplement=&class_name=%2806%2E1%2E1%2E%29Intestinal%20anthelminthics%3Cbr%3E|archivedate=2017年3月5日|df=}}</ref> 。在美國，一劑的售價約為18美元<ref name=AHFS2015/>。

==醫療用途==

甲苯咪唑為抗[[线虫动物门|線蟲類]]寄生蟲的特效藥，包含[[蟯蟲|蟯蟲]]、[[线虫动物门|线虫]]、[[絛蟲綱|絛蟲]]、{{le|鉤蟲|Hookworm}}、以及[[鞭蟲|鞭蟲]]。

此外，甲苯咪唑也可治療尚未離開消化道的初期[[旋毛蟲病|旋毛蟲病]]，但離開消化道的旋毛蟲即必須以其他藥物治療，因為此藥物難溶於血<ref name = "Goodman">Petri WA in Brunton LL, Chabner BA, Knollmann BC, Ed. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 12th ed., Chapter 42. McGraw-Hill, 2011 New York.</ref>。單獨使用此藥可以治療旋毛蟲輕度或中度的寄生蟲感染，但其殺蟲效果相當緩慢。若重症患者使用此藥物，則可能使寄生蟲自消化系統中逸出，導致[[盲腸炎|盲腸炎]]、膽道問題，或腸穿孔。為了避免此問題，重症病患可以在治療前使用[[哌嗪|驅蛔靈]]，或完全替代甲苯咪唑。因為[[哌嗪|驅蛔靈]]會使蟲體癱瘓，使其由糞便排出。<ref>Martin AR in Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, 8th edition, Doerge RF, ed. J.B. Lippincott, 1982, Chapter 4</ref>。甲苯咪唑很少拿來治療[[包囊蟲病|包囊蟲病]]，因為研究顯示其效果不佳。<ref>{{cite web|title=Mebendazole|url=http://www.drugs.com/monograph/mebendazole.html|website=drugs.com|accessdate=25 January 2015|archive-date=2015-09-07|archive-url=https://web.archive.org/web/20150907003126/http://www.drugs.com/monograph/mebendazole.html|dead-url=no}}</ref>

甲苯咪唑和其他苯并咪唑类藥物對於线虫的幼虫和成虫阶段都有效，對於蛔虫和鞭虫也可以杀卵。虫体會慢的麻痹而死亡，可能要幾天後才不會在糞便中出現<ref name = Goodman />。

===特定族群===
甲苯咪唑的[[懷孕分級|懷孕分級]]是C，會對[[懷孕|懷孕]]中的動物造成影響，但對於懷孕中婦女的影響沒有足夠臨床研究，目前尚不知道此藥是否會藉哺乳影響胎兒。<ref name = Harrison>Finberg R, Fingeroth J in Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo, Ed. Harrison's Principles of Internal Medicine, 18th ed., McGraw-Hill, 2012, Chapter 217.</ref>

==不良反应==
有時甲苯咪唑會造成腹泻，腹痛，和肝酶升高，在少數的案例中，甲苯咪唑會造成有危險性的低白血球計數、{{tsl|en|thrombocytopenia|低血小板计数}}及脫髮<ref name = Harrison /><ref>{{cite journal |author=Andersohn F, Konzen C, Garbe E |title=Systematic review: agranulocytosis induced by nonchemotherapy drugs |journal=Ann. Intern. Med. |volume=146 |issue=9 |pages=657–65 |date=May 2007 |pmid=17470834 |doi=10.7326/0003-4819-146-9-200705010-00009 |url=http://annals.org/article.aspx?articleid=734449 |access-date=2015-04-01 |archive-date=2016-03-15 |archive-url=https://web.archive.org/web/20160315032517/http://annals.org/article.aspx?articleid=734449 |dead-url=no }}</ref>，以及{{tsl|en|agranulocytosis|粒细胞缺乏症}}的風險。

===藥物互相作用===
[[卡马西平|卡马西平]](Carbamazepine)、[[苯妥英|苯妥英]]（Phenytoin，或稱Diphenyl hydantoin）會降低血漿中甲苯咪唑的濃度，[[西咪替丁|西咪替丁]](Cimetidine) 不會顯著提昇甲苯咪唑的濃度（和西咪替丁與[[阿苯达唑|阿苯达唑]]的影響不同），和其總系統吸收不高的結果一致<ref>{{cite web 
| title = Drug Interactions 
| url = http://www.medicinechestonline.co.uk/static/professional2/drug_interactions.htm 
| publisher = Medicine chest 
| accessdate = 2008-05-06 
| archive-url = https://web.archive.org/web/20070206161215/http://www.medicinechestonline.co.uk/static/professional2/drug_interactions.htm 
| archive-date = 2007-02-06 
| dead-url = yes 
}}</ref><ref>{{Cite journal 
| author = Luder PJ, Siffert B, Witassek F, Meister F, Bircher J
| title = Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions 
| url = https://archive.org/details/sim_european-journal-of-clinical-pharmacology_1986-12_31_4/page/443
| journal = European journal of clinical pharmacology 
| volume = 31 
| issue = 4 
| pages = 443–448 
| year = 1986 
| pmid = 3816925
| doi=10.1007/bf00613522
| last2 = Siffert 
| last3 = Witassek 
| last4 = Meister 
| last5 = Bircher 
}}</ref>。

若甲苯咪唑和高劑量的[[甲硝唑|甲硝唑]](Metronidazole) 一起服用，會出現[[史蒂芬斯－強森症候群|史蒂芬斯－強森症候群]]及更嚴重的{{tsl|en|toxic epidermal necrolysis|中毒性表皮壞死鬆解症}}<ref name="pmid12604501">{{Cite j
ournal 
| author = Chen, K. T.; Twu, S. J.; Chang, H. J.; Lin, R. S.
| title = Outbreak of Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis Associated with Mebendazole and Metronidazole Use Among Filipino Laborers in Taiwan 
| journal = American Journal of Public Health 
| volume = 93 
| issue = 3 
| pages = 489–492 
| year = 2003 
| pmid = 12604501 
| pmc = 1447769
| doi=10.2105/ajph.93.3.489
}}</ref>。

==藥物機制==
一般認為甲苯咪唑的機制如下：選擇性地抑制寄生蟲微管的合成，破壞其腸細胞中已有的細胞質微管，使其無法攝取葡萄糖和其他營養物質，從而降低蠕蟲的活動力，最終死亡<ref name = Goodman />。

==價格及廠商==
甲苯咪唑是[[通用名药物|通用名药物]]<ref name=Ric2012>{{cite book|last1=Hamilton|first1=Richard J.|title=Tarascon pocket pharmacopoeia|date=2012|publisher=Jones & Bartlett Learning|location=Burlington, Mass.|isbn=9781449624286|page=33|edition=13|url=https://books.google.ca/books?id=BmKOS-b0s08C&pg=PA355|access-date=2016-03-16|archive-date=2016-03-05|archive-url=https://web.archive.org/web/20160305074305/https://books.google.ca/books?id=BmKOS-b0s08C&pg=PA355|dead-url=no}}</ref>，成本在美金0.004元至0.04元之間<ref name=GlobP2014/>，在美國一劑約美金18元<ref name=AHFS2015/>。甲苯咪唑是由像[[強生公司|強生公司]]等國際廠商及一些通用藥製造商所販售<ref>{{Citation
 |url          = http://zenrx.org/
 |accessdate   = 2014-06-12
 |archive-url  = https://web.archive.org/web/20150630053931/http://zenrx.org/
 |archive-date = 30 June 2015
 |title        = Global Pharmaceutical Pricing and Reimbursement Database
 |publisher    = zenRx Research
 |deadurl      = yes
}}</ref>。

==研究==
許多研究指出甲苯咪唑有潛在的抗腫瘤性質，不論是[[体外|体外]]或是[[在活体|在活体]]的實驗，甲苯咪唑可以顯著抑制癌細胞的成長、遷移及轉移形成{{tsl|en|adrenocortical carcinoma|腎上腺皮質癌}}<ref name="pmid17581752">{{cite journal | author = Martarelli D, Pompei P, Baldi C, Mazzoni G | title = Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice | journal = Cancer Chemother. Pharmacol. | volume = 61 | issue = 5 | pages = 809–17 |date=April 2008 | pmid = 17581752 | doi = 10.1007/s00280-007-0538-0 }}</ref>。[[肺癌|肺癌]]細胞經過甲苯咪唑處理後，其有絲分裂停滯，之後[[胱天蛋白酶|胱天蛋白酶]]活化，釋放[[細胞色素c|細胞色素c]]，隨後細胞會凋亡死亡<ref name="pmid12479701">{{cite journal | author = Sasaki J, Ramesh R, Chada S, Gomyo Y, Roth JA, Mukhopadhyay T | title = The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells | journal = Mol. Cancer Ther. | volume = 1 | issue = 13 | pages = 1201–9 |date=November 2002 | pmid = 12479701 | doi = }}</ref>。甲苯咪唑會引發人類肺癌細胞的凋亡反應，效果和劑量和時間有關<ref name="pmid12231542">{{cite journal | author = Mukhopadhyay T, Sasaki J, Ramesh R, Roth JA | title = Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo | journal = Clin. Cancer Res. | volume = 8 | issue = 9 | pages = 2963–9 |date=September 2002 | pmid = 12231542 | doi = }}</ref>，也會使耐化療藥的[[黑色素瘤|黑色素瘤]]細胞因{{tsl|en|Bcl-2|Bcl-2}}不活化而凋亡<ref name="pmid18667591">{{cite journal | author = Doudican N, Rodriguez A, Osman I, Orlow SJ | title = Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells | journal = Mol. Cancer Res. | volume = 6 | issue = 8 | pages = 1308–15 |date=August 2008 | pmid = 18667591 | doi = 10.1158/1541-7786.MCR-07-2159 }}</ref>。
== 參考文獻 ==
{{reflist|35em}}

<!--{{Anthelmintics}}-->

[[Category:驅蟲藥|Category:驅蟲藥]]
[[Category:苯并咪唑|Category:苯并咪唑]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]
[[Category:氨基甲酸酯|Category:氨基甲酸酯]]
[[Category:芳族酮|Category:芳族酮]]
[[Category:致畸原|Category:致畸原]]